MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 222 filers reported holding MIRATI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.61 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $146,666 | +270.7% | 3,367 | +207.5% | 0.00% | – |
| Q2 2023 | $39,562 | -62.7% | 1,095 | -61.6% | 0.00% | – |
| Q1 2023 | $106,149 | +27.3% | 2,855 | +55.1% | 0.00% | – |
| Q4 2022 | $83,416 | -69.7% | 1,841 | -53.3% | 0.00% | -100.0% |
| Q3 2022 | $275,000 | +21.1% | 3,938 | +16.9% | 0.00% | – |
| Q2 2022 | $227,000 | +45.5% | 3,369 | +77.5% | 0.00% | – |
| Q1 2022 | $156,000 | +147.6% | 1,898 | +351.9% | 0.00% | – |
| Q4 2021 | $63,000 | -26.7% | 420 | -13.9% | 0.00% | – |
| Q3 2021 | $86,000 | +95.5% | 488 | +79.4% | 0.00% | – |
| Q2 2021 | $44,000 | +63.0% | 272 | +73.2% | 0.00% | – |
| Q1 2021 | $27,000 | +42.1% | 157 | +84.7% | 0.00% | – |
| Q4 2020 | $19,000 | +850.0% | 85 | +553.8% | 0.00% | – |
| Q3 2020 | $2,000 | -66.7% | 13 | -70.5% | 0.00% | – |
| Q4 2019 | $6,000 | +50.0% | 44 | -15.4% | 0.00% | – |
| Q3 2019 | $4,000 | -82.6% | 52 | -76.8% | 0.00% | – |
| Q2 2019 | $23,000 | +91.7% | 224 | +38.3% | 0.00% | – |
| Q1 2019 | $12,000 | – | 162 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $116,595,216 | 81.37% |
| ORACLE INVESTMENT MANAGEMENT INC | 201,400 | $7,488,052 | 7.25% |
| Paradigm Biocapital Advisors LP | 1,396,779 | $51,932,243 | 4.92% |
| Octagon Capital Advisors LP | 750,000 | $27,885,000 | 4.01% |
| Boxer Capital, LLC | 2,000,000 | $74,360 | 3.65% |
| Artal Group S.A. | 1,537,709 | $57,172 | 3.40% |
| Avoro Capital Advisors LLC | 5,555,555 | $206,555,535 | 3.06% |
| RTW INVESTMENTS, LP | 3,643,114 | $135,450,979 | 2.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 244,000 | $9,071,920 | 2.53% |
| Kynam Capital Management, LP | 499,853 | $18,584,535 | 2.40% |